IRADIMED CORP (IRMD) Fundamental Analysis & Valuation

NASDAQ:IRMD • US46266A1097

Current stock price

101.78 USD
+0.81 (+0.8%)
At close:
101.78 USD
0 (0%)
After Hours:

This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IRMD Profitability Analysis

1.1 Basic Checks

  • IRMD had positive earnings in the past year.
  • In the past year IRMD had a positive cash flow from operations.
  • In the past 5 years IRMD has always been profitable.
  • IRMD had a positive operating cash flow in each of the past 5 years.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M 20M 25M

1.2 Ratios

  • IRMD's Return On Assets of 20.67% is amongst the best of the industry. IRMD outperforms 98.94% of its industry peers.
  • IRMD has a Return On Equity of 23.76%. This is amongst the best in the industry. IRMD outperforms 96.30% of its industry peers.
  • The Return On Invested Capital of IRMD (21.02%) is better than 97.88% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 9.31%.
  • The 3 year average ROIC (20.45%) for IRMD is below the current ROIC(21.02%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROIC 21.02%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • With an excellent Profit Margin value of 26.82%, IRMD belongs to the best of the industry, outperforming 96.83% of the companies in the same industry.
  • In the last couple of years the Profit Margin of IRMD has grown nicely.
  • IRMD has a better Operating Margin (31.20%) than 98.41% of its industry peers.
  • IRMD's Operating Margin has improved in the last couple of years.
  • The Gross Margin of IRMD (76.75%) is better than 88.36% of its industry peers.
  • IRMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IRMD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
  • Compared to 1 year ago, IRMD has more shares outstanding
  • The number of shares outstanding for IRMD has been increased compared to 5 years ago.
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • IRMD has an Altman-Z score of 57.86. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IRMD (57.86) is better than 98.94% of its industry peers.
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 57.86
ROIC/WACC1.98
WACC10.64%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.3 Liquidity

  • IRMD has a Current Ratio of 7.98. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IRMD (7.98) is better than 87.30% of its industry peers.
  • IRMD has a Quick Ratio of 6.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • IRMD has a Quick ratio of 6.84. This is amongst the best in the industry. IRMD outperforms 87.83% of its industry peers.
Industry RankSector Rank
Current Ratio 7.98
Quick Ratio 6.84
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IRMD Growth Analysis

3.1 Past

  • IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.36%, which is quite good.
  • Measured over the past years, IRMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 36.18% on average per year.
  • Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 14.43% in the last year.
  • Measured over the past years, IRMD shows a very strong growth in Revenue. The Revenue has been growing by 21.45% on average per year.
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.02% on average over the next years. This is quite good.
  • Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 10.59% on average per year.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. IRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 53.01 indicates a quite expensive valuation of IRMD.
  • Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 67.72% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.61, IRMD is valued quite expensively.
  • A Price/Forward Earnings ratio of 47.97 indicates a quite expensive valuation of IRMD.
  • Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than 67.72% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (22.79), we can say IRMD is valued expensively.
Industry RankSector Rank
PE 53.01
Fwd PE 47.97
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • IRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 66.67% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than the industry average as 70.90% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 78.71
EV/EBITDA 45.37
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)5.05
PEG (5Y)1.47
EPS Next 2Y11.02%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. IRMD Dividend Analysis

5.1 Amount

  • IRMD has a yearly dividend return of 0.71%, which is pretty low.
  • IRMD's Dividend Yield is rather good when compared to the industry average which is at 0.24. IRMD pays more dividend than 91.01% of the companies in the same industry.
  • With a Dividend Yield of 0.71, IRMD pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.71%

5.2 History

  • IRMD has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • 66.90% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP66.9%
EPS Next 2Y11.02%
EPS Next 3YN/A
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IRMD Fundamentals: All Metrics, Ratios and Statistics

IRADIMED CORP

NASDAQ:IRMD (3/25/2026, 8:00:02 PM)

After market: 101.78 0 (0%)

101.78

+0.81 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-04
Inst Owners60.49%
Inst Owner Change3.31%
Ins Owners36.78%
Ins Owner Change-0.61%
Market Cap1.30B
Revenue(TTM)83.81M
Net Income(TTM)22.48M
Analysts82.5
Price Target122.4 (20.26%)
Short Float %6.49%
Short Ratio7.07
Dividend
Industry RankSector Rank
Dividend Yield 0.71%
Yearly Dividend1.18
Dividend Growth(5Y)N/A
DP66.9%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-23
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.78%
Min EPS beat(2)1.27%
Max EPS beat(2)10.29%
EPS beat(4)4
Avg EPS beat(4)5.61%
Min EPS beat(4)0.43%
Max EPS beat(4)10.44%
EPS beat(8)7
Avg EPS beat(8)6.02%
EPS beat(12)10
Avg EPS beat(12)6.52%
EPS beat(16)14
Avg EPS beat(16)7.03%
Revenue beat(2)2
Avg Revenue beat(2)2.2%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3%
Revenue beat(4)3
Avg Revenue beat(4)0.84%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)3%
Revenue beat(8)4
Avg Revenue beat(8)0.28%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)7
Avg Revenue beat(16)0.02%
PT rev (1m)21.21%
PT rev (3m)21.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)-1.89%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 53.01
Fwd PE 47.97
P/S 15.52
P/FCF 78.71
P/OCF 52.14
P/B 13.75
P/tB 14.26
EV/EBITDA 45.37
EPS(TTM)1.92
EY1.89%
EPS(NY)2.12
Fwd EY2.08%
FCF(TTM)1.29
FCFY1.27%
OCF(TTM)1.95
OCFY1.92%
SpS6.56
BVpS7.4
TBVpS7.14
PEG (NY)5.05
PEG (5Y)1.47
Graham Number17.88
Profitability
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROCE 26.52%
ROIC 21.02%
ROICexc 43.68%
ROICexgc 47.04%
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
FCFM 19.72%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)54.98%
ROICexgc(5y)60.13%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-13.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 722.21%
Cap/Sales 10.05%
Interest Coverage 250
Cash Conversion 91.34%
Profit Quality 73.51%
Current Ratio 7.98
Quick Ratio 6.84
Altman-Z 57.86
F-Score6
WACC10.64%
ROIC/WACC1.98
Cap/Depr(3y)948.96%
Cap/Depr(5y)635.99%
Cap/Sales(3y)11.43%
Cap/Sales(5y)7.92%
Profit Quality(3y)64.21%
Profit Quality(5y)73.8%
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.04%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.68%
FCF growth 3Y26.52%
FCF growth 5Y26.12%
OCF growth 1Y-2.64%
OCF growth 3Y35.44%
OCF growth 5Y33.79%

IRADIMED CORP / IRMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 8 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


Can you provide the profitability details for IRADIMED CORP?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?

The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 53.01 and the Price/Book (PB) ratio is 13.75.


Can you provide the financial health for IRMD stock?

The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.